Quite intersting overview of the European pharma market
by the European Federation of Pharmaceutical Industries
Association (EFPIA)
Its in Acrobat Reader: efpia.org
PH A R M A C E U T I C A L MA R K E T
VA L U E (AT E X-FA C T O RY P R I C E S)
EFPIA 1997 Euro million
Austria 1,345
Belgium 2,197
Denmark 811
Finland 918
France 13,875
Germany 15,735
Greece 1,027
Ireland 479
Italy 8,908
Netherlands 1,908
Norway 649
Portugal 1,563
Spain 5,305
Sweden 1,676
Switzerland 1,532
Turkey 1,765
United Kingdom 7,881
Total 67,574
PAY M E N T F O R PH A R M A C E U T I C A L S
B Y STAT U T O RY HE A LT H IN S U R A N C E
SY S T E M S/ NAT I O N A L HE A LT H
SE RV I C E S
EFPIA 1997 Euro million
Austria 1,217
Belgium 1,697
Denmark 653
Finland 559
France 14,122(*)
Germany 16,313
Greece 1,545
Ireland 299
Italy 6,038
Netherlands 3,022
Norway 762
Portugal 786
Spain 5,738
Sweden 1,456
Switzerland 1,512
Turkey n.a.
United Kingdom 7,881
Total 63,600
The members of this organization:
ME M B E R CO M PA N I E S
MEMBERS
Akzo Nobel-Pharma Netherlands
Almirall-Prodesfarma Spain
Ares-Serono Switzerland
Astra Sweden
Baxter United States
Bayer Germany
Beaufour Ipsen France
Boehringer Ingelheim Germany
Bristol Myers Squibb United States
Chiesi Farmaceutici Italy
Eli Lilly & Co United States
Laboratorios Esteve Spain
Glaxo Wellcome United Kingdom
Hoechst Marion Roussel Germany
Johnson & Johnson United States
Knoll Germany
Leo Pharmaceutical Products Denmark
H. Lundbeck Denmark
Menarini Italy
E. Merck Germany
Merck & Co United States
Novartis Switzerland
Novo Nordisk Denmark
Pfizer United States
Pharmacia & Upjohn United States
Rhône-Poulenc Pharma France
Roche Switzerland
Sanofi France
Schering Germany
Schering-Plough United States
Searle United States
Laboratoires Servier France
Sigma-Tau Italy
SmithKline Beecham United Kingdom
Solvay Belgium
Synthélabo France
UCB Pharma Belgium
Warner Lambert United States
Wyeth-Ayerst (AHP) United States
Zambon Group Italy
Zeneca United Kingdom
And one notable quote:
By the time a medicinal product is placed on the market,
an average of 10 to 12 years will have elapsed since the synthesis
of the new active substance; |
